
TTRX Stock Forecast & Price Target
TTRX Analyst Ratings
Bulls say
Turn Therapeutics Inc. is positioned favorably in the biotechnology sector, primarily due to its proprietary PermaFusion technology, which enhances the efficacy and safety profiles of its drug candidates targeting dermatological conditions. The company’s strategic focus on moderate to severe eczema opens access to a significant addressable market of approximately 16.5 million individuals in the U.S., bolstered by favorable reimbursement dynamics and strong physician adoption rates. Additionally, opportunities for expansion into both eczema and onychomycosis markets could further increase revenue potential, particularly with the projected treatment pricing for onychomycosis set at $10,000 per course, reflecting a substantial therapeutic market need.
Bears say
Turn Therapeutics Inc operates within the clinical-stage biotechnology sector, focusing on dermatological and infectious disease products, yet it faces significant challenges that may negatively impact its stock outlook. The company's targeted conditions, such as eczema and onychomycosis, represent sizable markets with low treatment penetration, high recurrence rates, and modest cure rates, all of which suggest difficulties in achieving sustainable commercial success. Additionally, as a small-cap company, Turn Therapeutics is subject to heightened volatility and risks, which may deter potential investors despite the innovative nature of its proprietary PermaFusion technology.
This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TTRX Analyst Forecast & Price Prediction
Start investing in TTRX
Order type
Buy in
Order amount
Est. shares
0 shares